International ClinicsMedical News
International Clinics Newsroom · · 1 min read
Daily

FDA approves pirtobrutinib as first-line treatment for chronic lymphocytic leukemia

  • On 2 October 2026 the FDA approved Jaypirca (pirtobrutinib) for adults with previously untreated chronic lymphocytic leukemia.
  • The pirtobrutinib approval also covers small lymphocytic lymphoma, for patients with no known 17p deletion.
  • In BRUIN CLL-313, pirtobrutinib cut the risk of progression or death by about 80% versus bendamustine plus rituximab.
  • Pirtobrutinib was previously approved only for relapsed or refractory disease.
Microscope image of red and white blood cells
Microscope image of red and white blood cells Photo: American Association for Cancer Research (AACR)
Published:

The US Food and Drug Administration approved Eli Lilly's Jaypirca (pirtobrutinib) on 2 October 2026 for adults with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion. The drug moves into first-line treatment after being limited to previously treated patients.

What pirtobrutinib is

Pirtobrutinib is a non-covalent Bruton tyrosine kinase (BTK) inhibitor taken as a 200 mg tablet once daily until disease progression or unacceptable toxicity.

Trial and results

Approval rests on BRUIN CLL-313, a randomized open-label trial of 282 patients assigned equally to pirtobrutinib or chemoimmunotherapy (bendamustine plus rituximab). With a median follow-up of 28 months, median progression-free survival was not reached with pirtobrutinib versus 33.5 months with the comparator (hazard ratio 0.20). Overall survival data are immature; there were 3 deaths (2.1%) versus 10 (7.1%).

Side effects

The most common side effects were upper respiratory infections (27%), rash (22%) and COVID-19 (21%), and serious adverse reactions occurred in 28% of patients. Warnings include infections, bleeding, low blood counts and heart rhythm problems.

Sources: US Food and Drug Administration (FDA), AJMC, American Association for Cancer Research (AACR)

This story is relayed from the source named above; responsibility for its content rests with the original source.

FAQ

What is new in the FDA approval of pirtobrutinib?

On 2 October 2026 the FDA approved pirtobrutinib (Jaypirca) as first-line treatment for adults with CLL or SLL without a known 17p deletion.

How is pirtobrutinib taken?

Pirtobrutinib is taken as a 200 mg tablet once daily until the disease progresses or side effects become unacceptable.

What did pirtobrutinib show in BRUIN CLL-313?

In BRUIN CLL-313, pirtobrutinib cut the risk of progression or death by about 80% (hazard ratio 0.20) versus bendamustine plus rituximab.

What are the common side effects of pirtobrutinib?

The most common side effects of pirtobrutinib are upper respiratory infections, rash and COVID-19, with warnings for infection, bleeding and heart rhythm problems.

Has pirtobrutinib been shown to extend overall survival?

The effect of pirtobrutinib on overall survival is not yet known because BRUIN CLL-313 survival data are still immature.

How would you rate this story?
5,958
Latest news
A fluoride-free gel that may rebuild tooth enamel, from the University of Nottingham Jackson 5's Marlon Jackson reveals he has lived with prostate cancer for four years Tip of the day: get your flu vaccine early, before winter peaks Every plant-based food in a UK study contained fungal toxins, all within EU guideline levels Tip of the day: spit, don't rinse, after brushing your teeth Energy drinks appear 11 times more often in cardiac arrest reports, preliminary study finds ISAPS global survey: eyelid surgery leads, breast lift grows fastest and filler declines Hippocrates: "Life is short, and Art long" Born on this day: William Beaumont and the hole in a stomach that rewrote digestion Tip of the day: sleep at least 7 hours a night, on a regular schedule
The latest-news bar is closed. You can bring it back any time with the “Latest news” button in the menu.